|
1
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma J, Niu M, Yang W, Zang L and Xi Y: Role
of relaxin-2 in human primary osteosarcoma. Cancer Cell Int.
13:592013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bacci G, Rocca M, Salone M, Balladelli A,
Ferrari S, Palmerini E, Forni C and Briccoli A: High grade
osteosarcoma of the extremities with lung metastases at
presentation: Treatment with neoadjuvant chemotherapy and
simultaneous resection of primary and metastatic lesions. J Surg
Oncol. 98:415–420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Messerschmitt PJ, Garcia RM, Abdul-Karim
FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop
Surg. 17:515–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eccles SA and Welch DR: Metastasis: Recent
discoveries and novel treatment strategies. Lancet. 369:1742–1757.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hughes DP: Strategies for the targeted
delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv.
6:1311–1321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kerosuo L and Bronner-Fraser M: What is
bad in cancer is good in the embryo: Importance of EMT in neural
crest development. Semin Cell Dev Biol. 23:320–332. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thompson EW, Newgreen DF and Tarin D:
Carcinoma invasion and metastasis: A role for
epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walsh LA and Damjanovski S: IGF-1
increases invasive potential of MCF 7 breast cancer cells and
induces activation of latent TGF-β1 resulting in epithelial to
mesenchymal transition. Cell Commun Signal. 9:102011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Graham TR, Zhau HE, Odero-Marah VA,
Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW and O'Regan
RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1
drives epithelial-to-mesenchymal transition in human prostate
cancer cells. Cancer Res. 68:2479–2488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jentzsch T, Robl B, Husmann M,
Bode-Lesniewska B and Fuchs B: Worse prognosis of osteosarcoma
patients expressing IGF-1 on a tissue microarray. Anticancer Res.
34:3881–3889. 2014.PubMed/NCBI
|
|
15
|
Jentzsch T, Robl B, Husmann M,
Bode-Lesniewska B and Fuchs B: Worse prognosis of osteosarcoma
patients expressing IGF-1 on a tissue microarray. Anticancer Res.
34:3881–3889. 2014.PubMed/NCBI
|
|
16
|
de Groot S, Gelderblom H, Fiocco M, Bovée
JV, van der Hoeven JJ, Pijl H and Kroep JR: Serum levels of IGF-1
and IGF-BP3 are associated with event-free survival in adult Ewing
sarcoma patients treated with chemotherapy. Onco Targets Ther.
10:2963–2970. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Yu XH, Yan YG, Wang C and Wang
WJ: PI3K/Akt signaling in osteosarcoma. Clin Chim Acta.
444:182–192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Lan T, Zhang W, Dong L, Kang N, Fu
M, Liu B, Liu K, Zhang C, Hou J and Zhan Q: Dasatinib enhances
cisplatin sensitivity in human esophageal squamous cell carcinoma
(ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Arch
Biochem Biophys. 575:38–45. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu H, Fan F, Liu Z, Shen C, Wang A and Lu
Y: Norcantharidin combined with EGFR-TKIs overcomes HGF-induced
resistance to EGFR-TKIs in EGFR mutant lung cancer cells via
inhibition of Met/PI3k/Akt pathway. Cancer Chemother Pharmacol.
76:307–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H,
Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression
via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell
carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamoto Y, De Velasco MA, Kura Y, Nozawa
M, Hatanaka Y, Oki T, Ozeki T, Shimizu N, Minami T, Yoshimura K, et
al: Evaluation of in vivo responses of sorafenib therapy in a
preclinical mouse model of PTEN-deficient of prostate cancer. J
Transl Med. 13:1502015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang C, Li H, Shen C, Lai J, Shi Z, Liu B
and Tao HM: Genistein potentiates the anti-cancer effects of
gemcitabine in human osteosarcoma via the downregulation of Akt and
nuclear factor-κB pathway. Anticancer Agents Med Chem. 12:554–563.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu LB, Jiang J, Zhu XP, Wang TF, Chen XY,
Luo QF, Shu Y, Liu ZL and Huang SH: Knockdown of Aurora-B inhibits
osteosarcoma cell invasion and migration via modulating
PI3K/Akt/NF-κB signaling pathway. Int J Clin Exp Pathol.
7:3984–3991. 2014.PubMed/NCBI
|
|
24
|
Olt S and Oznas O: Investigation of the
vitamin B12 deficiency with peripheral neuropathy in patients with
type 2 diabetes mellitus treated using metformin. North Clin
Istanb. 4:233–236. 2017.PubMed/NCBI
|
|
25
|
Cho SW, Yi KH, Han SK, Sun HJ, Kim YA, Oh
BC, Park YJ and Park DJ: Therapeutic potential of metformin in
papillary thyroid cancer in vitro and in vivo. Mol Cell Endocrinol.
393:24–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lengyel E, Litchfield LM, Mitra AK, Nieman
KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W and Romero
IL: Metformin inhibits ovarian cancer growth and increases
sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol.
212:479.e471–479.e410. 2015. View Article : Google Scholar
|
|
27
|
Lau YK, Du X, Rayannavar V, Hopkins B,
Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, et al:
Metformin and erlotinib synergize to inhibit basal breast cancer.
Oncotarget. 5:10503–10517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi
M, Yang M and Han B: Metformin inhibits epithelial-mesenchymal
transition in prostate cancer cells: Involvement of the tumor
suppressor miR30a and its target gene SOX4. Biochem Biophys Res
Commun. 452:746–752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Z, Cheng X, Wang Y, Han R, Li L,
Xiang T, He L, Long H, Zhu B and He Y: Metformin inhibits the
IL-6-induced epithelial-mesenchymal transition and lung
adenocarcinoma growth and metastasis. PloS One. 9:e958842014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao F, Huang W, Zhang Y, Tang S, Zheng L,
Ma F, Wang Y, Tang H and Li X: Hes1 promotes cell proliferation and
migration by activating Bmi-1 and PTEN/Akt/GSK3β pathway in human
colon cancer. Oncotarget. 6:38667–38680. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang G, Yuan J and Li K: EMT transcription
factors: Implication in osteosarcoma. Med Oncol. 30:6972013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lindsey BA, Markel JE and Kleinerman ES:
Osteosarcoma overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Duo J, Ma Y, Wang G, Han X and Zhang C:
Metformin synergistically enhances antitumor activity of histone
deacetylase inhibitor trichostatin a against osteosarcoma cell
line. DNA Cell Biol. 32:156–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mimeault M and Batra SK: Interplay of
distinct growth factors during epithelial mesenchymal transition of
cancer progenitor cells and molecular targeting as novel cancer
therapies. Ann Oncol. 18:1605–1619. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng
X, Zhu Z, Jiao H, Lin J, Jiang K, et al: Hepatitis B virus X
protein represses miRNA-148a to enhance tumorigenesis. J Clin
Invest. 123:630–645. 2013.PubMed/NCBI
|
|
37
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nielsen-Preiss SM, Silva SR and Gillette
JM: Role of PTEN and Akt in the regulation of growth and apoptosis
in human osteoblastic cells. J Cell Biochem. 90:964–975. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li T, Xiao Y and Huang T: HIF1α induced
upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by
inactivating the PTEN/AKT signaling pathway. Oncol Rep.
39:1072–1080. 2018.PubMed/NCBI
|
